By Brad Sorensen, CFA NASDAQ:SCLX READ THE FULL SCLX RESEARCH REPORT Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on addressing one of the biggest issues facing humanity today—that of the overuse of opioids. Scilex is focused on developing non-opioid pain management products that provide the relief patients so desperately need, while … Read more
NASDAQ:EVAX Anthony Kraus: Hello, and welcome to Virtual Investor Conferences. My name is Anthony Kraus and on behalf of OTC Markets, as well as our co-host, Zacks Small Cap Research, we’re very pleased you have joined us for our next live presentation from the Evaxion Biotech. Our session will be moderated by Brad Sorensen, Senior … Read more
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreciation and amortization (EBITDA) and earnings estimates. Ligand is a biopharmaceutical royalty … Read more
By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT POET Inks Deal With Mitsubishi to Design and Market 1.6T and 3.2T Engines Together On Sept. 19th, POET (NASDAQ:POET) announced a deal with Mitsubishi Electric to co-develop integrated optical engine chipsets for 3.2T pluggable transceivers. Mitsubishi Electric will contribute its 400G Electro-absorption Modulator Integrated Lasers … Read more
By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company’s AI models, novel targets within … Read more
